# Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia

> **NCT07696481** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Zhujiang Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed or Refractory Acute Leukemia
- Relapsed or Refractory Acute Lymphoblastic Leukemia
- Relapsed or Refractory Acute Myeloid Leukemia (AML)

## Interventions

- **BIOLOGICAL:** PID23 Injection

## Key facts

- **NCT ID:** NCT07696481
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-05-30
- **Final completion:** 2030-03-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07696481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07696481, "Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07696481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*